Pharmaceutical producers are rushing to build specialized fill-finish manufacturing capacity to address persistent structural shortages of GLP-1 receptor agonist medications.
Contract Manufacturing Bottlenecks
Global CDMO capacity remains severely constrained. Building and validating compliant sterile fill-finish facilities requires an average capital outlay of $500 million and 36 months.
Payer Coverage and Economic Impact
Insurance providers and national healthcare services are imposing strict coverage criteria to manage expenditures. Total cost burdens are prompting policy reviews regarding long-term preventive treatment funding.